SiBionics announced today that it unveiled its GS3 continuous glucose monitor (CGM), which now has CE mark approval. Our sister site, Drug Delivery Business News, reports that the company unveiled the device — which it touts as the world’s thinnest CGM — at last week’s 18th International Conference on Advanced Technologies & Treatments for Diabetes […]
SiBionics
Report: Court says SiBio can’t sell CGM in some European countries amid Abbott IP battle
JUVE-Patent reports that The Hague recently handed down two new decisions in a CGM patent battle between Abbott and SiBio. One case saw an Abbott patent infringement application shot down, while the other granted the U.S. medtech giant’s claim. The granted one could mean SiBio can’t distribute its CGMs in Germany, France, the Netherlands and […]
Report: Abbott files trio of patent lawsuits over CGM tech in Europe
Abbott (NYSE:ABT) filed three patent lawsuits against SiBionics and its distribution partner in Europe, JUVE-Patent reports. The lawsuits include patent infringement allegations centered around continuous glucose monitoring (CGM) devices, according to the report. Abbott filed them against China-based SiBionics and its sales partner Umedwings at the Unified Patent Court. SiBionics develops, manufactures and distributes CGM […]
SiBionics wins CE mark for 14-day CGM
SiBionics announced today that it received CE mark approval in Europe for its GS1 continuous glucose monitoring (CGM) system. The company designed its CGM system to provide healthcare providers and patients with data necessary for maintaining glucose control. It offers 14 days of calibration-free continuous glucose monitoring and can transmit data to monitoring devices or […]
